In vivo assessment of Lewy body and beta-amyloid copathologies in idiopathic normal pressure hydrocephalus: prevalence and associations with clinical features and surgery outcome.


Journal

Fluids and barriers of the CNS
ISSN: 2045-8118
Titre abrégé: Fluids Barriers CNS
Pays: England
ID NLM: 101553157

Informations de publication

Date de publication:
07 Sep 2022
Historique:
received: 06 05 2022
accepted: 25 08 2022
entrez: 7 9 2022
pubmed: 8 9 2022
medline: 11 9 2022
Statut: epublish

Résumé

Idiopathic normal pressure hydrocephalus (iNPH) is a clinico-radiological syndrome of elderly individuals likely sustained by different neurodegenerative changes as copathologies. Since iNPH is a potentially reversible condition, assessing neurodegenerative pathologies in vitam through CSF biomarkers and their influence on clinical features and surgical outcome represents crucial steps. We measured α-synuclein seeding activity related to Lewy body (LB) pathology by the real-time quaking-induced conversion assay (RT-QuIC) and Alzheimer disease core biomarkers (proteins total-tau, phospho-tau, and amyloid-beta) by immunoassays in the cerebrospinal fluid (CSF) of 293 iNPH patients from two independent cohorts. To compare the prevalence of LB copathology between iNPH participants and a control group representative of the general population, we searched for α-synuclein seeding activity in 89 age-matched individuals who died of Creutzfeldt-Jakob disease (CJD). Finally, in one of the iNPH cohorts, we also measured the CSF levels of neurofilament light chain protein (NfL) and evaluated the association between all CSF biomarkers, baseline clinical features, and surgery outcome at 6 months. Sixty (20.5%) iNPH patients showed α-synuclein seeding activity with no significant difference between cohorts. In contrast, the prevalence observed in CJD was only 6.7% (p = 0.002). Overall, 24.0% of iNPH participants showed an amyloid-positive (A+) status, indicating a brain co-pathology related to Aβ deposition. At baseline, in the Italian cohort, α-synuclein RT-QuIC positivity was associated with higher scores on axial and upper limb rigidity (p = 0.003 and p = 0.011, respectively) and lower MMSEc scores (p = 0.003). A+ patients showed lower scores on the MMSEc (p = 0.037) than A- patients. Higher NfL levels were also associated with lower scores on the MMSEc (rho = -0.213; p = 0.021). There were no significant associations between CSF biomarkers and surgical outcome at 6 months (i.e. responders defined by decrease of 1 point on the mRankin scale). Prevalent LB- and AD-related neurodegenerative pathologies affect a significant proportion of iNPH patients and contribute to cognitive decline (both) and motor impairment (only LB pathology) but do not significantly influence the surgical outcome at 6 months. Their effect on the clinical benefit after surgery over a more extended period remains to be determined.

Sections du résumé

BACKGROUND BACKGROUND
Idiopathic normal pressure hydrocephalus (iNPH) is a clinico-radiological syndrome of elderly individuals likely sustained by different neurodegenerative changes as copathologies. Since iNPH is a potentially reversible condition, assessing neurodegenerative pathologies in vitam through CSF biomarkers and their influence on clinical features and surgical outcome represents crucial steps.
METHODS METHODS
We measured α-synuclein seeding activity related to Lewy body (LB) pathology by the real-time quaking-induced conversion assay (RT-QuIC) and Alzheimer disease core biomarkers (proteins total-tau, phospho-tau, and amyloid-beta) by immunoassays in the cerebrospinal fluid (CSF) of 293 iNPH patients from two independent cohorts. To compare the prevalence of LB copathology between iNPH participants and a control group representative of the general population, we searched for α-synuclein seeding activity in 89 age-matched individuals who died of Creutzfeldt-Jakob disease (CJD). Finally, in one of the iNPH cohorts, we also measured the CSF levels of neurofilament light chain protein (NfL) and evaluated the association between all CSF biomarkers, baseline clinical features, and surgery outcome at 6 months.
RESULTS RESULTS
Sixty (20.5%) iNPH patients showed α-synuclein seeding activity with no significant difference between cohorts. In contrast, the prevalence observed in CJD was only 6.7% (p = 0.002). Overall, 24.0% of iNPH participants showed an amyloid-positive (A+) status, indicating a brain co-pathology related to Aβ deposition. At baseline, in the Italian cohort, α-synuclein RT-QuIC positivity was associated with higher scores on axial and upper limb rigidity (p = 0.003 and p = 0.011, respectively) and lower MMSEc scores (p = 0.003). A+ patients showed lower scores on the MMSEc (p = 0.037) than A- patients. Higher NfL levels were also associated with lower scores on the MMSEc (rho = -0.213; p = 0.021). There were no significant associations between CSF biomarkers and surgical outcome at 6 months (i.e. responders defined by decrease of 1 point on the mRankin scale).
CONCLUSIONS CONCLUSIONS
Prevalent LB- and AD-related neurodegenerative pathologies affect a significant proportion of iNPH patients and contribute to cognitive decline (both) and motor impairment (only LB pathology) but do not significantly influence the surgical outcome at 6 months. Their effect on the clinical benefit after surgery over a more extended period remains to be determined.

Identifiants

pubmed: 36071460
doi: 10.1186/s12987-022-00368-2
pii: 10.1186/s12987-022-00368-2
pmc: PMC9454182
doi:

Substances chimiques

Amyloid beta-Peptides 0
Biomarkers 0
Peptide Fragments 0
alpha-Synuclein 0
tau Proteins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

71

Subventions

Organisme : Sigrid Juselius Foundation and Academy of Finland
ID : Kuopio University Hospital VTR Fund
Organisme : Italian Ministry of Health
ID : "Ricerca corrente"

Informations de copyright

© 2022. The Author(s).

Références

Acta Neurol Scand. 2007 Nov;116(5):333-9
pubmed: 17922727
J Am Geriatr Soc. 1991 Feb;39(2):142-8
pubmed: 1991946
AJR Am J Roentgenol. 1987 Aug;149(2):351-6
pubmed: 3496763
Neurobiol Aging. 2003 Mar-Apr;24(2):197-211
pubmed: 12498954
Am J Med. 1986 Mar;80(3):429-34
pubmed: 3953620
Mov Disord. 2007 Jan;22(1):41-7
pubmed: 17115387
Neuropathol Appl Neurobiol. 2001 Aug;27(4):314-25
pubmed: 11532162
Neurology. 2021 Aug 31;97(9):e930-e940
pubmed: 34210822
Acta Neurol Scand. 2012 Oct;126(4):229-37
pubmed: 22587624
Neurology. 2006 Apr 11;66(7):1100-2
pubmed: 16606927
Neurology. 1998 Apr;50(4):1122-7
pubmed: 9566405
Dement Geriatr Cogn Disord. 2008;25(1):37-45
pubmed: 18025828
Alzheimers Res Ther. 2018 Jan 11;10(1):3
pubmed: 29368621
J Neurol Sci. 1965 Jul-Aug;2(4):307-27
pubmed: 5889177
Neurology. 2017 Jul 4;89(1):88-100
pubmed: 28592453
J Neurol Neurosurg Psychiatry. 1988 Jun;51(6):745-52
pubmed: 2841426
Parkinsonism Relat Disord. 2019 Sep;66:117-124
pubmed: 31358442
Stroke. 2001 Jun;32(6):1318-22
pubmed: 11387493
Ann Neurol. 2017 Oct;82(4):503-513
pubmed: 28892572
Stroke. 1988 Dec;19(12):1497-500
pubmed: 3201508
J Neurol. 2017 Oct;264(10):2141-2148
pubmed: 28879446
J Clin Med. 2021 Mar 06;10(5):
pubmed: 33800840
Fluids Barriers CNS. 2019 Jul 25;16(1):21
pubmed: 31340831
J Neurosurg. 2018 Jan 19;130(1):121-129
pubmed: 29350601
Acta Neuropathol Commun. 2020 Jul 25;8(1):117
pubmed: 32711575
World Neurosurg. 2016 Jun;90:348-356
pubmed: 26970480
J Alzheimers Dis. 2019;68(2):723-733
pubmed: 30883350
Alzheimers Dement. 2011 Sep;7(5):509-13
pubmed: 21723206
Acta Neurochir (Wien). 2022 Jul;164(7):1719-1746
pubmed: 35230552
J Neurol. 2018 Oct;265(10):2434-2441
pubmed: 30155736
Mov Disord. 2021 Jan;36(1):124-132
pubmed: 33151012
Acta Neurochir (Wien). 2017 Dec;159(12):2293-2300
pubmed: 28889317
Acta Neurochir (Wien). 2013 Oct;155(10):1977-80
pubmed: 23975646
Neuropathol Appl Neurobiol. 2012 Feb;38(1):72-86
pubmed: 21696417
Cerebrospinal Fluid Res. 2008 Apr 25;5:9
pubmed: 18439296
Neurosurgery. 2005 Sep;57(3 Suppl):S4-16; discussion ii-v
pubmed: 16160425
Neurology. 2014 Apr 22;82(16):1449-54
pubmed: 24682964
Acta Neuropathol. 2020 Jul;140(1):49-62
pubmed: 32342188
Fluids Barriers CNS. 2022 Feb 14;19(1):15
pubmed: 35164790
Fluids Barriers CNS. 2022 Feb 5;19(1):11
pubmed: 35123528
J Neurol. 2022 Apr;269(4):2022-2029
pubmed: 34468800
Acta Neuropathol Commun. 2018 Feb 9;6(1):7
pubmed: 29422107
J Neurol Sci. 2022 Feb 15;433:120019
pubmed: 34674853
Ann Clin Transl Neurol. 2018 Dec 14;6(2):263-273
pubmed: 30847359
Lancet Neurol. 2021 Mar;20(3):235-246
pubmed: 33609480

Auteurs

Giulia Giannini (G)

IRCCS Istituto delle Scienze Neurologiche di Bologna, Bellaria Hospital, Via Altura 1/8, 40139, Bologna, Italy.
Department of Biomedical and Neuromotor Sciences (DIBINEM), University of Bologna, Bologna, Italy.

Simone Baiardi (S)

IRCCS Istituto delle Scienze Neurologiche di Bologna, Bellaria Hospital, Via Altura 1/8, 40139, Bologna, Italy.
Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, Bologna, Italy.

Sofia Dellavalle (S)

IRCCS Istituto delle Scienze Neurologiche di Bologna, Bellaria Hospital, Via Altura 1/8, 40139, Bologna, Italy.

Corrado Zenesini (C)

IRCCS Istituto delle Scienze Neurologiche di Bologna, Bellaria Hospital, Via Altura 1/8, 40139, Bologna, Italy.

Sabina Cevoli (S)

IRCCS Istituto delle Scienze Neurologiche di Bologna, Bellaria Hospital, Via Altura 1/8, 40139, Bologna, Italy.
Department of Biomedical and Neuromotor Sciences (DIBINEM), University of Bologna, Bologna, Italy.

Nils Danner (N)

Department of Neurosurgery, Kuopio University Hospital, 70029, Kuopio, Finland.
Neurosurgery, Institute of Clinical Medicine, University of Eastern Finland, 70210, Kuopio, Finland.

Henna-Kaisa Jyrkkänen (HK)

Department of Neurosurgery, Kuopio University Hospital, 70029, Kuopio, Finland.
Neurosurgery, Institute of Clinical Medicine, University of Eastern Finland, 70210, Kuopio, Finland.

Marcello Rossi (M)

IRCCS Istituto delle Scienze Neurologiche di Bologna, Bellaria Hospital, Via Altura 1/8, 40139, Bologna, Italy.

Barbara Polischi (B)

IRCCS Istituto delle Scienze Neurologiche di Bologna, Bellaria Hospital, Via Altura 1/8, 40139, Bologna, Italy.

Corinne Quadalti (C)

IRCCS Istituto delle Scienze Neurologiche di Bologna, Bellaria Hospital, Via Altura 1/8, 40139, Bologna, Italy.

Camilla Stefanini (C)

Department of Biomedical and Neuromotor Sciences (DIBINEM), University of Bologna, Bologna, Italy.

Pietro Cortelli (P)

IRCCS Istituto delle Scienze Neurologiche di Bologna, Bellaria Hospital, Via Altura 1/8, 40139, Bologna, Italy.
Department of Biomedical and Neuromotor Sciences (DIBINEM), University of Bologna, Bologna, Italy.

David Milletti (D)

IRCCS Istituto delle Scienze Neurologiche di Bologna, Bellaria Hospital, Via Altura 1/8, 40139, Bologna, Italy.

Sanna-Kaisa Herukka (SK)

Department of Neurology, Kuopio University Hospital, 70029, Kuopio, Finland.
Neurology, Institute of Clinical Medicine, University of Eastern Finland, 70210, Kuopio, Finland.

Giorgio Palandri (G)

IRCCS Istituto delle Scienze Neurologiche di Bologna, Bellaria Hospital, Via Altura 1/8, 40139, Bologna, Italy.

Ville Leinonen (V)

Department of Neurosurgery, Kuopio University Hospital, 70029, Kuopio, Finland.
Neurosurgery, Institute of Clinical Medicine, University of Eastern Finland, 70210, Kuopio, Finland.

Piero Parchi (P)

IRCCS Istituto delle Scienze Neurologiche di Bologna, Bellaria Hospital, Via Altura 1/8, 40139, Bologna, Italy. piero.parchi@unibo.it.
Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, Bologna, Italy. piero.parchi@unibo.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH